Quoin Pharmaceuticals is pleased to announce our fourth quarter and 2024 full-year results. 2024 was without a doubt the most significant year in Quoin’s history. This progress was particularly exemplified in the clinical development of QRX003, our product candidate for Netherton Syndrome, and we are encouraged by the positive data our ongoing studies are generating. Read more here:?https://bit.ly/4bQ5bMt ?#nethertonsyndrome #QNRX #financialresults
Quoin Pharmaceuticals
制药业
Ashburn,Virginia 587 位关注者
Rare Diseases are only rare if you don't live with one.
关于我们
Founded in 2018, Quoin is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. The company plans to establish a sales infrastructure to commercialize its products in both U.S. and Europe and seeks to enter into strategic licensing partnerships for all other territories. We are dedicated to finding unique solutions for rare and orphan indications and will continue to expand our pipeline of products to address the unmet needs of underserved patient populations. To learn more about Quoin Pharmaceuticals please visit our website: www.quoinpharma.com
- 网站
-
https://quoinpharma.com/
Quoin Pharmaceuticals的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Ashburn,Virginia
- 类型
- 上市公司
- 创立
- 2018
地点
-
主要
US,Virginia,Ashburn,20148
Quoin Pharmaceuticals员工
动态
-
Carmon McTigue’s son, Silas, was born with Netherton Syndrome. At first, doctors only guessed about which disease her son had, leaving Carmon and her husband with no definitive answers about their son’s condition. Silas suffered from failure to thrive multiple times and was hospitalized 15-20 times in his first years of life due to severe infections. After seven months and consultations with dozens of specialists her son was finally properly diagnosed with Netherton Syndrome. From the moment he was born, Silas faced an uphill battle. Netherton Syndrome isn’t just a skin condition—it’s a daily struggle with pain, inflammation, and uncertainty. There is no approved treatment. No cure. Yet despite it all, Silas keeps moving forward. This past year, he took on another challenge—playing football for the first time. With extra precautions and a determined spirit, he stepped onto the field, proving that while Netherton Syndrome is a part of his life, it does not define him. For Silas and so many others, the fight continues—not just for resilience, but for real solutions. A treatment for Netherton Syndrome is desperately needed. Watch his journey and join us in raising awareness and support for the Netherton Syndrome community.? #netherton #QNRX #nethertonsyndrome #nethertonsyndromecommunity Quoin Pharmaceuticals https://lnkd.in/eVMseTfP
-
-
Quoin Pharmaceuticals is pleased to announce the filing of US and International patent applications for novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare diseases including microcystic lymphatic malformations, venous malformations and angiofibromas.?Read more here:?https://bit.ly/3DcqB9P? #QNRX #rarediseases #patent?
-
-
At Quoin Pharmaceuticals, we believe that rare diseases are only rare if you don’t live with one. Today, on Rare Disease Day, we are proud to debut the first episode of our NETHERTON NOW "Living with Netherton" video series—a powerful initiative aimed at shedding light on the profound and often misunderstood impact of Netherton Syndrome. This first episode features Carmon McTigue, whose son was born with Netherton Syndrome, a devastating genetic disorder that remains largely unknown. Carmon shares the emotional journey of navigating misdiagnoses, hospitalizations, and the harsh reality that no approved treatment or cure exists. Her story reflects the resilience, strength, and determination of families who face this disease every day. Through the NETHERTON NOW campaign, Quoin is committed to raising awareness, advocacy, and education for this underserved community. Future episodes will continue to highlight patient and family experiences, emphasizing the urgent need for greater research and treatment options. At Quoin, we are working to change this reality. We are currently conducting four clinical trials to evaluate QRX003, our lead candidate for Netherton Syndrome. Our mission is clear: to provide hope where there has been none and to deliver a treatment for this neglected disease. We extend our deepest gratitude to the McTigue family for sharing their story and helping us bring visibility to this condition. Their voices—and those of countless others in the rare disease community—deserve to be heard. hashtag #rarediseaseday2025 Watch the full episode here: https://lnkd.in/e8JDt9Wv Learn more about our clinical trials: https://lnkd.in/gGaJ4xnZ https://lnkd.in/eNJzVNV8
The McTigue Family – A Journey to Diagnosis, the Search for Answers, and Hope for a Cure
https://www.youtube.com/
-
Quoin Pharmaceuticals is pleased to announce the global premiere of the “NETHERTON NOW” video series?with first episode?set to launch on Rare Disease Day,?this Friday - February 28, 2025. This series is dedicated?to?giving a voice to?the?patients?and families directly affected by?Netherton Syndrome. Read more:?https://bit.ly/41v42X2? #netherton #QNRX #rarediseaseday ?
-
-
As Rare Disease Day approaches, we recognize the urgent need for breakthrough treatments for conditions like Netherton Syndrome (NS)—a rare, life-threatening genetic disorder with no FDA-approved therapies. Currently, we are conducting four ongoing clinical studies evaluating QRX003’s safety and efficacy as a potential first-in-class treatment for NS. With each study, we move closer to delivering a breakthrough therapy for the Netherton community. It is time to bring hope where there is currently none. Find out more:?https://bit.ly/412BPph hashtag #Rarediseaseday2025 #NETHERTONNOW
-
-
Rare Disease Day on February 28, 2025, is a critical reminder that while individual rare diseases may be uncommon, together they impact over?300 million people worldwide. For those living with?Netherton Syndrome—a devastating genetic condition with no approved treatment—awareness and advocacy are crucial to driving research and progress. Through?NETHERTON?NOW, Quoin’s initiative dedicated to supporting the Netherton Syndrome community, we are committed to amplifying voices, supporting patients, and pushing for meaningful change. At Quoin, we know?rare diseases are only rare if you don’t live with one? This Rare Disease Day, we stand with patients and families in the fight for better treatments, greater awareness, and a brighter future. Because everyone deserves to feel comfortable in their own skin Visit us at?https://nethertonnow.com?#Rarediseaseday2025 #NETHERTONNOW
-
-
Quoin Pharmaceuticals is pleased to announce the launch of ‘NETHERTON NOW’, a multi-pronged media campaign to raise awareness of the rare disease Netherton Syndrome and its impact on patients, family members and caregivers. Read more here:?https://bit.ly/42HP4y3?#nethertonsyndrome #QNRX #nethertonnow #QRX003
-
-
Quoin Pharmaceuticals is pleased to announce further clinical evidence of QRX003 effectiveness in Netherton Syndrome. This data set has provided the clearest clinical evidence to date that the active ingredient in QRX003 is a competitive broad spectrum serine protease inhibitor and the discontinuation of treatment with QRX003 results in a complete reversal of all clinical benefits derived from continued treatment with the product. Read more here:?https://bit.ly/40wds2S? #nethertonsyndrome #QNRX #clinicaltrials
-
-
Quoin Pharmaceuticals is pleased to announce additional positive interim data from its ongoing open-label Netherton Syndrome study for its first subject dosed twice daily with QRX003 which demonstrated clinical benefits observed across all measured endpoints. Read more here:?https://bit.ly/4a4IkvK ?#QNRX #nethertonsyndrome #QRX003 #positivedata
-